TWI787260B - 具有新穎的組成物、組合物及其方法之標靶藥物救援 - Google Patents

具有新穎的組成物、組合物及其方法之標靶藥物救援 Download PDF

Info

Publication number
TWI787260B
TWI787260B TW107115320A TW107115320A TWI787260B TW I787260 B TWI787260 B TW I787260B TW 107115320 A TW107115320 A TW 107115320A TW 107115320 A TW107115320 A TW 107115320A TW I787260 B TWI787260 B TW I787260B
Authority
TW
Taiwan
Prior art keywords
formula
compound
heptane
dex
phenoxy
Prior art date
Application number
TW107115320A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842902A (zh
Inventor
史瑞尼瓦沙羅 維帕奇杜
漢斯 Ｊ 莫比烏斯
安東 貝斯帕洛夫
Original Assignee
德商艾克西法有限企業家公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by 德商艾克西法有限企業家公司 filed Critical 德商艾克西法有限企業家公司
Publication of TW201842902A publication Critical patent/TW201842902A/zh
Application granted granted Critical
Publication of TWI787260B publication Critical patent/TWI787260B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW107115320A 2017-05-04 2018-05-04 具有新穎的組成物、組合物及其方法之標靶藥物救援 TWI787260B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
US62/501,696 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
??PCT/US17/48748 2017-08-25
WOPCT/US17/48748 2017-08-25
US201862634162P 2018-02-22 2018-02-22
US62/634,162 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US62/635,554 2018-02-27
US62/636,099 2018-02-27
US201862636171P 2018-02-28 2018-02-28
US62/636,171 2018-02-28

Publications (2)

Publication Number Publication Date
TW201842902A TW201842902A (zh) 2018-12-16
TWI787260B true TWI787260B (zh) 2022-12-21

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107115320A TWI787260B (zh) 2017-05-04 2018-05-04 具有新穎的組成物、組合物及其方法之標靶藥物救援

Country Status (13)

Country Link
EP (1) EP3618819A4 (enExample)
JP (2) JP7514078B2 (enExample)
KR (2) KR102444803B1 (enExample)
CN (1) CN110831584B (enExample)
AU (2) AU2018261654A1 (enExample)
BR (1) BR112019022902A2 (enExample)
CA (2) CA3138116A1 (enExample)
IL (1) IL270326B2 (enExample)
MA (1) MA49464A (enExample)
RU (1) RU2760558C9 (enExample)
TW (1) TWI787260B (enExample)
WO (1) WO2018204713A1 (enExample)
ZA (1) ZA201908006B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
WO2020190971A1 (en) * 2019-03-18 2020-09-24 Avanir Pharmaceuticals, Inc. Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
WO2020246143A1 (ja) * 2019-06-06 2020-12-10 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN119432479B (zh) * 2023-08-04 2025-10-03 中国石油天然气股份有限公司 柴油机润滑油组合物及其制备方法
CN120987847A (zh) * 2024-11-29 2025-11-21 江苏恩华药业股份有限公司 一种氢溴酸右美沙芬的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2008009947A (es) 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
CA2685723C (en) * 2007-05-01 2013-06-18 Concert Pharmaceuticals Inc. Morphinan compounds
WO2008144764A1 (en) * 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2014138669A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
CA2907357A1 (en) * 2013-03-15 2014-09-18 Kinemed, Inc. Biomarkers
MY198587A (en) * 2014-09-14 2023-09-06 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
CA3034895A1 (en) * 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschrankt) Compositions and methods thereof
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
2000年06月，Canadian Journal of Anesthesia volume 47, 585，The role of dextromethorphan in pain control, Avi A. Weinbroum. *
European Journal of Pharmacology Volume 404, Issues 1–2, Pages 95-102，Antinociception in rat by sarpogrelate, a selective 5-HT2A receptor antagonist, is peripheral.HideakiObata.; *

Also Published As

Publication number Publication date
EP3618819A1 (en) 2020-03-11
JP2020518617A (ja) 2020-06-25
BR112019022902A2 (pt) 2020-05-19
CN110831584B (zh) 2023-03-10
IL270326B (en) 2022-10-01
RU2760558C2 (ru) 2021-11-29
AU2021215274B2 (en) 2022-11-03
JP2023143940A (ja) 2023-10-06
CN110831584A (zh) 2020-02-21
ZA201908006B (en) 2021-04-28
CA3062452A1 (en) 2018-11-08
AU2018261654A1 (en) 2019-11-14
RU2019137004A3 (enExample) 2021-06-04
WO2018204713A1 (en) 2018-11-08
RU2760558C9 (ru) 2022-02-22
IL270326A (enExample) 2018-05-03
KR102444803B1 (ko) 2022-09-19
JP7514078B2 (ja) 2024-07-10
RU2019137004A (ru) 2021-06-04
TW201842902A (zh) 2018-12-16
CA3062452C (en) 2023-10-24
IL270326B2 (en) 2023-02-01
KR20210130827A (ko) 2021-11-01
EP3618819A4 (en) 2021-01-20
AU2021215274A1 (en) 2021-09-02
KR20200062078A (ko) 2020-06-03
MA49464A (fr) 2020-04-29
CA3138116A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
TWI787260B (zh) 具有新穎的組成物、組合物及其方法之標靶藥物救援
JP7096813B2 (ja) 組成物及びその方法
CA3221280A1 (en) Enantiomeric entactogen compositions and methods of their use
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP5226053B2 (ja) ベンジルイソキノリン誘導体またはビスベンジルイソキノリン誘導体を含有する向精神薬、鎮痛薬および／または抗炎症薬、ならびに健康食品
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2024508545A (ja) セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
US20220296586A1 (en) Novel compositions, combinations, and methods thereof